Bloks | $1,500,000 | (Sep 26, 2024)
ujet.cx | $76,000,000 | (Sep 26, 2024)
DefectDojo | $7,000,000 | (Sep 26, 2024)
Genespire
Italy
- Milan, Lombardy
- 26/09/2024
- Series B
- $51,969,485
Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.
- Industry Biotechnology Research
- Website https://www.genespire.com/en/homepage/
- LinkedIn https://www.linkedin.com/company/genespire/
Related People
Karen AIACH PIGNETFounder
France -
ND
An experienced Chair and Board Member (publicly traded companies), Karen is an international biotechnology industry leader. She has 20+ years of experience, evolving from transaction support to successful entrepreneurship. Her focus over the last 15 years has been on genetic medicine for brain diseases. She founded and developed Lysogene, a leading biotechnology company in the CNS space, and raised €100 million in public and private markets. Her successes have led to the award of numerous prizes.
Tamnoon | $12,000,000 | (Sep 26, 2024)
Infact | $5,337,880 | (Sep 26, 2024)
hlpy | $20,073,258 | (Sep 26, 2024)
Flent | $776,762 | (Sep 26, 2024)
Outgo | $15,000,000 | (Sep 26, 2024)